TriangleNCT00364923 · OUTCOME
Overall Survival Per Independent Central Review
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- Full Range
- Time frame
- Assessed every 14 weeks while on treatment, and after disease progression no less frequently than every 6 months for up to 2 years after first dose.
What was measured
Calculated as date of death - date of enrollment +1, estimated using the product-limit estimator. Pts who had not died (no record of death) or were lost to follow-up were censored at the date of last contact. Pts who withdrew consent to participate in the study including consent to be followed, were censored on the date of withdrawal. Pts who withdrew from treatment without withdrawing consent were followed for survival status whenever possible.
Analysis population: Analysis was per protocol, based on the number of patients (pts) who had an event (death or censoring) at the time of data cut-off.
Groups in this outcome
Evaluable Population
All patients who received at least one dose of pralatrexate and had an eligible PTCL histopathological subtype confirmed by central pathology review.
| Group | Source count |
|---|---|
| Evaluable Population | 109 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Evaluable Population | 14.5 | Not reported | 1 | 24.1 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 1
- upper Limit
- 24.1
- value
- 14.5
- denoms
- counts
- group Id
- OG000
- value
- 109
- units
- Participants
- description
- Calculated as date of death - date of enrollment +1, estimated using the product-limit estimator. Pts who had not died (no record of death) or were lost to follow-up were censored at the date of last contact. Pts who withdrew consent to participate in the study including consent to be followed, were censored on the date of withdrawal. Pts who withdrew from treatment without withdrawing consent were followed for survival status whenever possible.
- dispersion Type
- Full Range
- groups
- description
- All patients who received at least one dose of pralatrexate and had an eligible PTCL histopathological subtype confirmed by central pathology review.
- id
- OG000
- title
- Evaluable Population
- param Type
- MEDIAN
- population Description
- Analysis was per protocol, based on the number of patients (pts) who had an event (death or censoring) at the time of data cut-off.
- reporting Status
- POSTED
- time Frame
- Assessed every 14 weeks while on treatment, and after disease progression no less frequently than every 6 months for up to 2 years after first dose.
- title
- Overall Survival Per Independent Central Review
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice